Director, Medical Information

About Summit

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s Team Is Inspired To Touch And Help Change Lives Through Summit’s Clinical Studies In The Field Of Oncology. Summit Has Multiple Global Phase 3 Clinical Studies, Including

• HARMONi:
  Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi‑3:
  Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first‑line metastatic NSCLC.
• HARMONi‑7:
  Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first‑line metastatic NSCLC.

• HARMONi‑GI3:
  Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

The Director, Medical Information (MI) is a strategic leader responsible for building, scaling, and overseeing the MI function to ensure launch readiness and ongoing scientific excellence. This role will architect the full MI infrastructure—including systems, processes, governance, and content strategy—to support the company’s first commercial launch and future portfolio expansion.

A critical component of this role is leading to the end‑to‑end development and maintenance of MI capabilities that enable swift onboarding, integration, and operational readiness of the MI call center vendor, ensuring seamless, compliant, and high quality interactions with healthcare professionals, patients, and internal stakeholders.

The Director will collaborate cross‑functionally with Medical Affairs, Regulatory, Safety, Clinical Development, Clinical Operations, Compliance, and Commercial partners to ensure MI is tightly aligned with scientific, regulatory, and business needs. This is a highly visible role requiring scientific depth, operational excellence, and the ability to build new capabilities in a fast‑paced environment.

• Lead and implement the design and build‑out of the MI infrastructure (i.e., MI Call Center), ensuring scalability, compliance, and readiness for US launch.
• Assist in developing the MI operating model, including workflows, governance, content strategy, and cross‑functional interfaces, both in the USA and globally.
• Serve as the internal expert on MI regulations, industry standards, and best practices.

• Develop external (Call Center‑specific) and internal (Summit‑specific) MI SOPs, work instructions, training materials, and quality monitoring processes to ensure consistent, compliant, and high‑quality responses.
• Ensure the call center is fully prepared for launch, including training, content availability, escalation pathways, and performance metrics.
• Proactively manage call center/contractors responsible for responding to MIRs (including escalations from the call center) from Health Care Providers.
• Monitor vendor performance, quality, and compliance; implement…